• cgoddard

  • Colin Goddard, Ph.D.
    Chairman & CEO

    Colin Goddard is an investor in the company and has been part of the leadership team since the inception of BlinkBio in 2015.  Dr. Goddard was formerly CEO of OSI Pharmaceuticals for 12 years, raising over $1.5 billion and overseeing the development, launch and commercialization of the lung cancer drug Tarceva through to OSI’s $4 billion acquisition by Astellas.  He also Chairs the board of Mission Therapeutics and is a board member of the drug conjugate company Endocyte (NASDAQ:ECYT).  Dr.Goddard obtained his PhD in cancer chemotherapy in the UK and completed post-doctoral training at the National Cancer Institute in Bethesda, MD.

  • mpingle

  • Maneesh Pingle, Ph.D.

    Maneesh Pingle has been part of the leadership team since the inception of BlinkBio in 2015 and oversees business development and operations.  He brings a multidisciplinary scientific background with training in pharmacy, medicinal and nucleic acid chemistry and molecular biology.  Dr. Pingle received his Ph.D. from Purdue University and his Bachelor’s degree in Pharmacy from the Bombay College of Pharmacy (India).

  • jwanner

  • Jutta Wanner, Ph.D.
    Vice-President & CSO

    Jutta Wanner has also been part of the leadership team since inception and is an experienced pharmaceutical industry executive having joined BlinkBio from Roche in Nutley, NJ where she was a co-lead in discovery chemistry.  She brings expertise across multiple therapeutic areas including oncology, inflammation and virology.  Dr. Wanner received her PhD from the University of Kansas and conducted her postdoctoral training at The Scripps Research Institute in San Diego.